The company announced a $350 million public offering on Monday shortly after revealing positive Phase II results for its ...

Corsera, which emerged in September 2025, aims to extend healthspan by reducing the risk of atherosclerotic cardiovascular disease (ASCVD). The biotech is developing an AI-enabled tool to predict ...

Though specific data for bepirovirsen remain under wraps, GSK plans to file for approval in the first quarter of 2026.

The acquisition is centered on Dark Blue Therapeutics' small-molecule degrader of the MLLT1 and MLLT3 proteins, which is ...

Jazz’s Ziihera and BeOne’s Tevimbra plus chemotherapy led to what Truist Securities dubbed one of the strongest overall ...

From biotech veterans to embattled modalities to a new wave of RNAi therapeutics, BioSpace’s NextGen Class of 2026 emerged ...

After a prolonged funding chill, investors say 2026 is shaping up for continued dealmaking and diversified bets beyond ...

In a year that saw advisory committees placed under a particularly bright microscope at the FDA, the agency held fewer ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

While Zenas’ obexelimab hit the primary endpoint in the Phase III INDIGO study, it came far below the efficacy threshold set ...

Families with Huntington’s need this to be true more than most. The devastating neurodegenerative disease is caused by a CAG ...

The fierce rivalry between Novo Nordisk and Eli Lilly is alive and well, as the two companies are expected to face off with ...